Alfresa Holdings and Hiroshima University Establish Joint Research Chair for Tick-Borne Diseases

Alfresa Holdings Corporation, along with its subsidiaries, has signed an agreement with Hiroshima University to establish a Joint Research Chair for Clinical Emerging Infectious Diseases at Hiroshima University Hospital, starting June 1, 2026. The research will focus on developing a rapid diagnostic kit for Severe Fever with Thrombocytopenia Syndrome (SFTS), a tick-borne viral infection. The initiative aims to strengthen countermeasures against tick-borne diseases and build diagnostic technologies for future emerging infectious diseases through industry-academia collaboration over an approximately five-year period.